MASLD/MASH Learning Center
Global, regional and national burden and trends of non-alcoholic fatty liver disease in women of reproductive age from 1990 to 2021: Insights from the Global burden of disease study 2021
May 2026
CONCLUSION: These findings provide critical epidemiological insights for global NAFLD prevention and underscore the need for targeted health policies for WCBA as a high-risk population.
Read More
Editorial: Adaptive immune regulation of non-alcoholic steatohepatitis (NASH)
May 2026
No abstract
Read More
Insights into Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: The Role of Fibrinogen and Pepsinogen
May 2026
CONCLUSION: Overall, both fibrinogen and pepsinogen appear to have a more significant negative impact on liver health and the progression of NAFLD than beneficial effects. Integrating assessments of fibrinogen and pepsinogen into clinical practice could facilitate earlier intervention strategies aimed at slowing disease progression.
Read More
The Relationship between Carotid Artery Stenosis and the Severity of Fatty Liver in Patients with Coronary Artery Disease Who Are Candidates for Angiography
May 2026
CONCLUSION: This study demonstrated that liver fibrosis severity (based on the FIB-4 index) is significantly associated with carotid artery stenosis and coronary artery involvement. Therefore, assessing liver fibrosis may serve as a predictive marker for cardiovascular risk in patients with NAFLD. The use of non-invasive methods such as FIB-4 alongside ultrasonography is recommended for fibrosis evaluation.
Read More
Retrospective analysis of predictors for significant hepatic inflammation in metabolic-associated fatty liver disease with chronic hepatitis B
May 2026
CONCLUSIONS: This clinical study was conducted based on histopathological findings and demonstrated that BMI, LSM, and HBV DNA are independent risk factors for the progression of hepatic inflammation in patients with MAFLD and HBV infection, whereas ALT served as an independent non-invasive predictor of this outcome. These findings provide a novel non-invasive approach for clinicians to assess the degree of hepatic inflammation when liver biopsy results are unavailable.
Read More
The oral-gut-liver axis: linking periodontal microbiota to the pathogenesis of liver diseases
May 2026
Oral microbiota plays a critical role in linking oral and systemic health, with dysbiosis closely associated with the onset and progression of chronic liver diseases. This review systematically examines the central role of the "oral-gut-liver axis" in hepatic pathophysiology. Epidemiological evidence has identified periodontitis and specific oral pathogens, such as Fusobacterium nucleatum (F. nucleatum), as independent risk factors for the progression of non-alcoholic fatty liver disease...
Read More
Electroacupuncture in the treatment of non-alcoholic fatty liver disease: mechanistic insights and therapeutic potential
May 2026
Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver disorder globally, driven by increasing rates of obesity, insulin resistance, and metabolic dysfunction. In the absence of approved pharmacological therapies, electroacupuncture (EA) has garnered attention as a promising adjunctive intervention. This review synthesizes recent advances in understanding the mechanistic underpinnings and therapeutic potential of EA in NAFLD. We discuss how EA modulates hepatic...
Read More
Hepatopulmonary syndrome as presentation of pediatric metabolic dysfunction-associated steatohepatitis
May 2026
Childhood obesity is rising and leading to serious co-morbidities, among which is metabolic dysfunction-associated steatotic liver disease (MASLD) predisposing individuals to cirrhosis. We describe a young 11-year-old Hispanic male who presented with hepatopulmonary syndrome secondary to cirrhotic portal hypertension from metabolic dysfunction-associated steatohepatitis (MASH), necessitating liver transplantation. Despite lifestyle modifications post-transplantation, the patient experienced...
Read More
Cryptogenic Pyogenic Liver Abscess as a Sentinel of Occult Colorectal Cancer: Successful Conservative Management of a Rare Presentation
May 2026
Pyogenic liver abscess (PLA) is an uncommon but serious infection, usually linked to biliary or intra-abdominal sources. When no clear cause is identified, the possibility of an underlying gastrointestinal malignancy, especially colorectal cancer (CRC), should always be considered. In some cases, a liver abscess may be the very first sign of an otherwise silent cancer. We report a 68-year-old woman with a history of breast cancer, chronic obstructive pulmonary disease, and non-alcoholic fatty...
Read More
A novel glucose-lipid metabolism-related indicator and its association with metabolic dysfunction-associated fatty liver disease: a cross-sectional study based on a health check-up population
May 2026
CONCLUSION: The CHG index was positively associated with MAFLD and showed good discriminatory ability in this large Chinese health check-up population. Although its performance was lower than that of the TyG index and FLI, it may still serve as a simple and accessible metabolic indicator for identifying individuals at higher risk of MAFLD in primary healthcare and health screening settings.
Read More
Gut microbes mediate the synergistic effects of dietary cholesterol and saturated fat in driving fibrosing MASH
May 2026
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately one-third of the global population and can progress to metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis, increasing the risk of cirrhosis, hepatocellular carcinoma, and mortality. Gut microbes driven by diets high in saturated fat, simple sugar, and cholesterol contribute to disease progression, yet the underlying mechanisms remain undefined. We explored the independent and synergistic...
Read More
Untargeted Metabolomic Analysis Reveals the Mechanism Underlying Swertia mussotii Treatment on Rats With Non-Alcoholic Fatty Liver Disease Using UPLC-Q-TOF/MS
May 2026
Swertia mussotii (SM) is a traditional Tibetan medicine and can effectively treat hepatopathies like non-alcoholic fatty liver disease (NAFLD). However, the mechanism by which it alleviates NAFLD is largely undetermined. In this study, we determined the efficacy of SM and its associated mechanism in NAFLD with in vivo and in vitro models. NAFLD was induced in mice by administering the high-fat diet (HFD) and in HepG2 cells via free fatty acid (FFA) stimulation. Treatment with SM significantly...
Read More